Literature DB >> 9426447

Integrin alpha v beta 6 enhances coxsackievirus B1 lytic infection of human colon cancer cells.

M V Agrez1, D R Shafren, X Gu, K Cox, D Sheppard, R D Barry.   

Abstract

Viral entry into host cells depends upon specific interactions between virus attachment proteins and cell surface receptors that enable virus binding and internalization of virus and/or the virus-receptor complex. We have recently reported that the ubiquitous cell surface molecule, decay-accelerating factor (DAF), is a major cell attachment receptor for Coxsackieviruses B1, B3, and B5. However, DAF permits only virus binding and not virus internalization, invoking the presence of secondary or accessory receptors. Among the known receptors for enteroviruses are members of the cell adhesion molecule family known as integrins. In the present study, we found that expression of the epithelial-restricted integrin, alpha v beta 6, on colonic epithelial cells significantly enhanced Coxsackievirus B1-mediated cell lysis. Importantly, the viral-mediated cell killing required the presence of the 11-amino-acid C-terminal cytoplasmic extension unique to the beta 6 subunit, providing the first evidence of regulation of viral infectivity by integrin cytoplasmic domains. These results indicate that alpha v beta 6 expression on intestinal epithelial cells critically affects Coxsackievirus B1 infectivity. This may be essential in the conversion of asymptomatic enterovirus infection into clinically apparent disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9426447     DOI: 10.1006/viro.1997.8831

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  14 in total

1.  Polarized entry of uropathogenic Afa/Dr diffusely adhering Escherichia coli strain IH11128 into human epithelial cells: evidence for alpha5beta1 integrin recognition and subsequent internalization through a pathway involving caveolae and dynamic unstable microtubules.

Authors:  J Guignot; M F Bernet-Camard; C Poüs; L Plançon; C Le Bouguenec; A L Servin
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

2.  Proteomic analysis of membrane proteins of vero cells: exploration of potential proteins responsible for virus entry.

Authors:  Donghua Guo; Qinghe Zhu; Hong Zhang; Dongbo Sun
Journal:  DNA Cell Biol       Date:  2013-11-28       Impact factor: 3.311

3.  Characterization of coxsackievirus B3 replication in human umbilical vein endothelial cells.

Authors:  A Kühnl; C Rien; K Spengler; N Kryeziu; A Sauerbrei; R Heller; A Henke
Journal:  Med Microbiol Immunol       Date:  2014-03-11       Impact factor: 3.402

Review 4.  Pathogenesis of Afa/Dr diffusely adhering Escherichia coli.

Authors:  Alain L Servin
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

5.  Picornavirus receptor down-regulation by plasminogen activator inhibitor type 2.

Authors:  D R Shafren; J Gardner; V H Mann; T M Antalis; A Suhrbier
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

6.  The epithelial integrin alphavbeta6 is a receptor for foot-and-mouth disease virus.

Authors:  T Jackson; D Sheppard; M Denyer; W Blakemore; A M King
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

Review 7.  Integrins and integrin-associated proteins in the cardiac myocyte.

Authors:  Sharon Israeli-Rosenberg; Ana Maria Manso; Hideshi Okada; Robert S Ross
Journal:  Circ Res       Date:  2014-01-31       Impact factor: 17.367

Review 8.  Cell adhesion molecules in the pathogenesis of and host defence against microbial infection.

Authors:  J R Kerr
Journal:  Mol Pathol       Date:  1999-08

Review 9.  Evolution of cell recognition by viruses: a source of biological novelty with medical implications.

Authors:  Eric Baranowski; Carmen M Ruiz-Jarabo; Nonia Pariente; Nuria Verdaguer; Esteban Domingo
Journal:  Adv Virus Res       Date:  2003       Impact factor: 9.937

10.  Viral cell entry induced by cross-linked decay-accelerating factor.

Authors:  D R Shafren
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.